Literature DB >> 18611986

Induction of human CD4+ regulatory T cells by mycophenolic acid-treated dendritic cells.

Christine Lagaraine1, Roxane Lemoine, Christophe Baron, Hubert Nivet, Florence Velge-Roussel, Yvon Lebranchu.   

Abstract

Depending on their degree of maturation, costimulatory molecule expression, and cytokine secretion, dendritic cells (DC) can induce immunity or tolerance. DC treated with mycophenolic acid during their maturation (MPA-DC) have a regulatory phenotype and may therefore provide a new approach to induce allograft tolerance. Purified CD4(+) T cells stimulated in a human in vitro model of mixed culture by allogeneic MPA-DC displayed much weaker proliferation than T cells activated by mature DC and were anergic. This hyporesponsiveness was alloantigen-specific. Interestingly, T cells stimulated by MPA-DC during long-term coculture in four 7-day cycles displayed potent, suppressive activity, as revealed by marked inhibition of the proliferation of naive and preactivated control T cells. These regulatory T cells (Tregs) appeared to have antigen specificity and were contact-dependent. Tregs induced by MPA-DC were CD25(+)glucocorticoid-induced TNFR(+)CTLA-4(+)CD95(+), secreted IL-5 and large amounts of IL-10 and TGF-beta, and displayed enhanced forkhead box p3 expression. These results obtained in vitro demonstrate that human MPA-DC can induce allospecific Tregs that may be exploited in cell therapy to induce allograft tolerance.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18611986     DOI: 10.1189/jlb.1007716

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  8 in total

1.  Successful neutrophil engraftment by reduced use of granulocyte colony-stimulating factor after allogeneic hematopoietic stem cell transplantation with mycophenolate mofetil for graft-versus-host disease prophylaxis.

Authors:  Atsuo Okamura; Kimikazu Yakushijin; Yumiko Inui; Yohei Funakoshi; Yuriko Kawamori; Takanobu Shimada; Masanori Toyoda; Naoko Chayahara; Naomi Kiyota; Yutaka Fujiwara; Toru Mukohara; Hiroshi Matsuoka; Katsuya Yamamoto; Hironobu Minami
Journal:  Int J Hematol       Date:  2011-04-22       Impact factor: 2.490

Review 2.  Immunotherapy with myeloid cells for tolerance induction.

Authors:  Mercedes Rodriguez-García; Peter Boros; Jonathan S Bromberg; Jordi C Ochando
Journal:  Curr Opin Organ Transplant       Date:  2010-08       Impact factor: 2.640

Review 3.  Pharmacologic targeting of regulatory T cells for solid organ transplantation: current and future prospects.

Authors:  Kassem Safa; Sindhu Chandran; David Wojciechowski
Journal:  Drugs       Date:  2015-11       Impact factor: 9.546

4.  Impact of immunosuppressive drugs on the therapeutic efficacy of ex vivo expanded human regulatory T cells.

Authors:  Cristiano Scottà; Giorgia Fanelli; Sec Julie Hoong; Marco Romano; Estefania Nova Lamperti; Mitalee Sukthankar; Giuliana Guggino; Henrieta Fazekasova; Kulachelvy Ratnasothy; Pablo D Becker; Behdad Afzali; Robert I Lechler; Giovanna Lombardi
Journal:  Haematologica       Date:  2015-10-15       Impact factor: 9.941

Review 5.  Therapeutic potential of tolerogenic dendritic cells in IBD: from animal models to clinical application.

Authors:  Raquel Cabezón; Daniel Benítez-Ribas
Journal:  Clin Dev Immunol       Date:  2013-11-12

Review 6.  Update on Dendritic Cell-Induced Immunological and Clinical Tolerance.

Authors:  Carolina Obregon; Rajesh Kumar; Manuel Antonio Pascual; Giuseppe Vassalli; Déla Golshayan
Journal:  Front Immunol       Date:  2017-11-20       Impact factor: 7.561

Review 7.  Potential Application of T-Follicular Regulatory Cell Therapy in Transplantation.

Authors:  Caroline Dudreuilh; Sumoyee Basu; Cristiano Scottà; Anthony Dorling; Giovanna Lombardi
Journal:  Front Immunol       Date:  2021-02-02       Impact factor: 7.561

8.  Gram-negative enterobacteria induce tolerogenic maturation in dexamethasone conditioned dendritic cells.

Authors:  Raquel Cabezón; Elena Ricart; Carolina España; Julián Panés; Daniel Benitez-Ribas
Journal:  PLoS One       Date:  2012-12-27       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.